Category: Press Release - Page 35 - Psychedelic Alpha

Read more about the article Wesana Health Announces Receipt of Short-Term Loan

Wesana Health Announces Receipt of Short-Term Loan

Post published:December 21, 2022
Post category:Press Release

Read more about the article The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital

The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital

Post published:December 16, 2022
Post category:Press Release

Read more about the article Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments

Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments

Post published:December 15, 2022
Post category:Press Release

Read more about the article FILAMENT HEALTH AND PSYENCE ANNOUNCE WORLDWIDE LICENSING AGREEMENT OF PSILOCYBIN CAPSULE FOR PALLIATIVE CARE

FILAMENT HEALTH AND PSYENCE ANNOUNCE WORLDWIDE LICENSING AGREEMENT OF PSILOCYBIN CAPSULE FOR PALLIATIVE CARE

Post published:December 15, 2022
Post category:Press Release

Read more about the article First Patient Dosed in Small Pharma’s Drug Interaction Study

First Patient Dosed in Small Pharma’s Drug Interaction Study

Post published:December 15, 2022
Post category:Press Release

Read more about the article Revive Therapeutics Ltd. Expands Life Offering to Quebec

Revive Therapeutics Ltd. Expands Life Offering to Quebec

Post published:December 15, 2022
Post category:Press Release

Read more about the article Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders

Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders

Post published:December 15, 2022
Post category:Press Release

Read more about the article FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder

FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder

Post published:December 15, 2022
Post category:Press Release

Read more about the article Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor

Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor

Post published:December 14, 2022
Post category:Press Release

Read more about the article Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100

Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100

Post published:December 13, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.